Skip to main content
OpenTrials
Completed

NCT Number: NCT02452684

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients

To investigate the safety and efficacy of administration of eszopiclone for 4 weeks in insomnia patients.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Osaka, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Insomnia participants who did not take eszopiclone before assessment
  • Participants who receive assessment by using sleep questionaries

Treatment and study plan

Eszopiclone

Drug

The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.

Other names: EZOP; Lunesta

Primary outcomes

  1. Assessment of overall improvement

    Time frame: Up to 4 weeks

    Participants will be interviewed regarding sleep improvement at 4 weeks after first dose or discontinuation relative to predose, and select the appropriate answer of: 1. Improved 2. Unchanged 3. Worse 4. Indiscernible

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 4 weeks

Sponsors and collaborators

Lead sponsor

Eisai Co., Ltd.

Industry

Registry information

Official study title

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients (Study LUN01S)

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
May 25, 2015
Registry last updated
Sep 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.